{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T11:38:47Z","timestamp":1793705927807,"version":"4.6.1"},"reference-count":32,"publisher":"Centers for Disease Control and Prevention (CDC)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Emerg. Infect. Dis."],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.3201\/eid2903.220989","type":"journal-article","created":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T19:11:55Z","timestamp":1677179515000},"page":"493-500","source":"Crossref","is-referenced-by-count":7,"title":["Yellow Fever Vaccine\u2013Associated Viscerotropic Disease among Siblings, S\u00e3o Paulo State, Brazil"],"prefix":"10.3201","volume":"29","author":[{"given":"Eder Gatti","family":"Fernandes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor Bertollo","family":"Gomes Porto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patr\u00edcia Mouta Nunes","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaro Nunes","family":"Duarte-Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria de Lourdes","family":"de Sousa Maia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Let\u00edcia Kegele","family":"Lignani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana Silva","family":"Nogueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriellen Vitiello","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia D\u2019Andretta","family":"Iglezias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta Morozetti","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena Keico","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1822","reference":[{"key":"key-10.3201\/eid2903.220989-202302181015-R1","unstructured":"Brazil Ministry of Health. Secretary of Health Surveillance. General coordination for the development of epidemiology in services. Health surveillance guide 2019 [cited 2022 Jun 15]. https:\/\/bvsms.saude.gov.br\/bvs\/publicacoes\/guia_vigilancia_saude_3ed.pdf"},{"key":"key-10.3201\/eid2903.220989-202302181015-R2","unstructured":"Epidemiological Surveillance Center. \u201cProf. Alexandre Vranjac.\u201d Epidemiological bulletin yellow fever update. 2022 [cited 2022 Jun 16]. https:\/\/www.saude.sp.gov.br\/cve-centro-de-vigilancia-epidemiologica-prof.-alexandre-vranjac\/areas-de-vigilancia\/doencas-de-transmisS\u00e3o-por-vetores-e-zoonoses\/agravos\/febre-amarela\/boletim-epidemiologico"},{"key":"key-10.3201\/eid2903.220989-202302181015-R3","doi-asserted-by":"publisher","first-page":"5038","DOI":"10.1016\/j.vaccine.2012.04.067","article-title":"Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data.","volume":"30","author":"Gershman","year":"2012","journal-title":"Vaccine"},{"key":"key-10.3201\/eid2903.220989-202302181015-R4","doi-asserted-by":"publisher","first-page":"4054","DOI":"10.1128\/JCM.01799-12","article-title":"Advanced yellow fever virus genome detection in point-of-care facilities and reference laboratories.","volume":"50","author":"Domingo","year":"2012","journal-title":"J Clin Microbiol"},{"key":"key-10.3201\/eid2903.220989-202302181015-R5","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0166-0934(03)00129-0","article-title":"Detection of yellow fever virus: a comparison of quantitative real-time PCR and plaque assay.","volume":"110","author":"Bae","year":"2003","journal-title":"J Virol Methods"},{"key":"key-10.3201\/eid2903.220989-202302181015-R6","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1128\/JCM.38.5.1823-1826.2000","article-title":"Standardization of immunoglobulin M capture enzyme-linked immunosorbent assays for routine diagnosis of arboviral infections.","volume":"38","author":"Martin","year":"2000","journal-title":"J Clin Microbiol"},{"key":"key-10.3201\/eid2903.220989-202302181015-R7","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1111\/his.13904","article-title":"Yellow fever and orthotopic liver transplantation: new insights from the autopsy room for an old but re-emerging disease.","volume":"75","author":"Duarte-Neto","year":"2019","journal-title":"Histopathology"},{"key":"key-10.3201\/eid2903.220989-202302181015-R8","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.1016\/j.vaccine.2005.01.089","article-title":"Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events.","volume":"23","author":"Khromava","year":"2005","journal-title":"Vaccine"},{"key":"key-10.3201\/eid2903.220989-202302181015-R9","doi-asserted-by":"publisher","first-page":"945","DOI":"10.3201\/eid0706.010605","article-title":"Advanced age a risk factor for illness temporally associated with yellow fever vaccination.","volume":"7","author":"Martin","year":"2001","journal-title":"Emerg Infect Dis"},{"key":"key-10.3201\/eid2903.220989-202302181015-R10","first-page":"244","article-title":"Age-related risk of adverse events following yellow fever vaccination in Australia.","volume":"28","author":"Lawrence","year":"2004","journal-title":"Commun Dis Intell Q Rep"},{"key":"key-10.3201\/eid2903.220989-202302181015-R11","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/S0140-6736(01)05327-2","article-title":"Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases.","volume":"358","author":"Martin","year":"2001","journal-title":"Lancet"},{"key":"key-10.3201\/eid2903.220989-202302181015-R12","doi-asserted-by":"publisher","first-page":"5974","DOI":"10.1016\/j.vaccine.2009.07.082","article-title":"Viscerotropic disease following yellow fever vaccination in Peru.","volume":"27","author":"Whittembury","year":"2009","journal-title":"Vaccine"},{"key":"key-10.3201\/eid2903.220989-202302181015-R13","first-page":"1","article-title":"Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"59","author":"Staples","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"key-10.3201\/eid2903.220989-202302181015-R14","doi-asserted-by":"publisher","first-page":"e20202486","DOI":"10.1084\/jem.20202486","article-title":"Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine.","volume":"218","author":"Bastard","year":"2021","journal-title":"J Exp Med"},{"key":"key-10.3201\/eid2903.220989-202302181015-R15","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.provac.2010.07.012","article-title":"Yellow fever vaccine post-marketing surveillance in Brazil.","volume":"2","author":"Martins","year":"2010","journal-title":"Procedia Vaccinol"},{"key":"key-10.3201\/eid2903.220989-202302181015-R16","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1006\/viro.2001.1168","article-title":"Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil.","volume":"290","author":"Galler","year":"2001","journal-title":"Virology"},{"key":"key-10.3201\/eid2903.220989-202302181015-R17","doi-asserted-by":"publisher","first-page":"8480","DOI":"10.1016\/j.vaccine.2007.08.061","article-title":"Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease.","volume":"25","author":"Belsher","year":"2007","journal-title":"Vaccine"},{"key":"key-10.3201\/eid2903.220989-202302181015-R18","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1086\/587844","article-title":"Immune response during adverse events after 17D-derived yellow fever vaccination in Europe.","volume":"197","author":"Bae","year":"2008","journal-title":"J Infect Dis"},{"key":"key-10.3201\/eid2903.220989-202302181015-R19","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1016\/j.vaccine.2021.05.101","article-title":"CCL3, CCL5, IL-15, IL-1Ra and VEGF compose a reliable algorithm to discriminate classes of adverse events following 17DD-YF primary vaccination according to cause-specific definitions.","volume":"39","author":"Fradico","year":"2021","journal-title":"Vaccine"},{"key":"key-10.3201\/eid2903.220989-202302181015-R20","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1086\/590187","article-title":"Case of yellow fever vaccine\u2014associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes.","volume":"198","author":"Pulendran","year":"2008","journal-title":"J Infect Dis"},{"key":"key-10.3201\/eid2903.220989-202302181015-R21","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1128\/CVI.00369-09","article-title":"Clinical and immunological insights on severe, adverse neurotropic and viscerotropic disease following 17D yellow fever vaccination.","volume":"17","author":"Silva","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"key-10.3201\/eid2903.220989-202302181015-R22","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/ni.1688","article-title":"Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans.","volume":"10","author":"Querec","year":"2009","journal-title":"Nat Immunol"},{"key":"key-10.3201\/eid2903.220989-202302181015-R23","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1084\/jem.20082292","article-title":"Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses.","volume":"205","author":"Gaucher","year":"2008","journal-title":"J Exp Med"},{"key":"key-10.3201\/eid2903.220989-202302181015-R24","doi-asserted-by":"publisher","first-page":"e01956","DOI":"10.1128\/mBio.01956-15","article-title":"Vaccine and wild-type strains of yellow fever virus engage distinct entry mechanisms and differentially stimulate antiviral immune responses.","volume":"7","author":"Fernandez-Garcia","year":"2016","journal-title":"MBio"},{"key":"key-10.3201\/eid2903.220989-202302181015-R25","doi-asserted-by":"publisher","first-page":"12392","DOI":"10.1128\/JVI.02149-13","article-title":"Dynamic viral dissemination in mice infected with yellow fever virus strain 17D.","volume":"87","author":"Erickson","year":"2013","journal-title":"J Virol"},{"key":"key-10.3201\/eid2903.220989-202302181015-R26","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1084\/jem.20182295","article-title":"Inherited IFNAR1 deficiency in otherwise healthy patients with adverse reaction to measles and yellow fever live vaccines.","volume":"216","author":"Hernandez","year":"2019","journal-title":"J Exp Med"},{"key":"key-10.3201\/eid2903.220989-202302181015-R27","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.vaccine.2019.12.018","article-title":"Immunogenicity and safety of fractional dose yellow fever vaccination: A systematic review and meta-analysis.","volume":"38","author":"Nnaji","year":"2020","journal-title":"Vaccine"},{"key":"key-10.3201\/eid2903.220989-202302181015-R28","doi-asserted-by":"publisher","first-page":"100131","DOI":"10.1016\/j.jvacx.2021.100131","article-title":"Yellow fever vaccination in Brazil: Short-term safety and immunogenicity in juvenile autoimmune rheumatic diseases.","volume":"10","author":"Emi Aikawa","year":"2021","journal-title":"Vaccine X"},{"key":"key-10.3201\/eid2903.220989-202302181015-R29","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/0092-1157(88)90034-0","article-title":"Studies on yellow fever vaccine. III\u2014Dose response in volunteers.","volume":"16","author":"Lopes Ode","year":"1988","journal-title":"J Biol Stand"},{"key":"key-10.3201\/eid2903.220989-202302181015-R30","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1186\/1471-2334-14-391","article-title":"Subdoses of 17DD yellow fever vaccine elicit equivalent virological\/immunological kinetics timeline.","volume":"14","author":"Campi-Azevedo","year":"2014","journal-title":"BMC Infect Dis"},{"key":"key-10.3201\/eid2903.220989-202302181015-R31","doi-asserted-by":"publisher","first-page":"e1993","DOI":"10.1371\/journal.pone.0001993","article-title":"Intradermally administered yellow fever vaccine at reduced dose induces a protective immune response: a randomized controlled non-inferiority trial.","volume":"3","author":"Roukens","year":"2008","journal-title":"PLoS One"},{"key":"key-10.3201\/eid2903.220989-202302181015-R32","doi-asserted-by":"publisher","first-page":"879","DOI":"10.4161\/hv.22982","article-title":"17DD yellow fever vaccine: a double blind, randomized clinical trial of immunogenicity and safety on a dose-response study.","volume":"9","author":"Martins","year":"2013","journal-title":"Hum Vaccin Immunother"}],"container-title":["Emerging Infectious Diseases"],"original-title":[],"link":[{"URL":"https:\/\/wwwnc.cdc.gov\/eid\/article\/29\/3\/22-0989_article","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T17:58:31Z","timestamp":1732989511000},"score":1,"resource":{"primary":{"URL":"https:\/\/wwwnc.cdc.gov\/eid\/article\/29\/3\/22-0989_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"URL":"https:\/\/doi.org\/10.3201\/eid2903.220989","relation":{},"ISSN":["1080-6040","1080-6059"],"issn-type":[{"value":"1080-6040","type":"print"},{"value":"1080-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3]]}}}